Merck & Co (MRK)
$85.81 0.17 (0.20%)
19:17 EDT MRK Stock Quote Delayed 30 Minutes
Previous Close $85.81
Market Cap 230.85B
PE Ratio 147.95
Volume (Avg. Vol.) 11.74M
Day's Range 84.94 - 86.30
52-Week Range 65.25 - 92.64
Dividend & Yield 1.92 (2.24%)
MRK Stock Predictions, Articles, and Merck & Co News
- From InvestorPlace
- From the Web
It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to watch.
Some traders consider Merck stock to be a safe Dow Jones type of investment. Yet, the Covid-19 vaccine angle could propel the share price.
Despite the economic challenges of the pandemic, Americans are spoiling their pets. Profit from that hot market with these top growth stocks.
Alexandria Real Estate Equities is the largest landlord in the US for laboratories and related offices.
Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.
MRK stock isn't bad. It has a reasonable valuation, okay growth and a solid dividend. But Merck isn't my favorite pick in biotech.
Merck (MRK) earnings for the pharmaceutical company's second quarter of 2020 have MRK stock up on Friday after beating estimates.
Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.
Merck stock has outperformed large-cap pharma stocks. But that's a low bar to clear, leaving investors with more attractive options elsewhere.
Moderna, a stock that doesn't reside in the Dow Jones Industrial Average, sent the blue chip index soaring to start the week.
In another instance of the market fighting off weak economic data, stocks rallied Thursday despite another spike in weekly jobless numbers.
Stocks swooned Wednesday after Federal Reserve Chairman Jerome Powell said the novel coronavirus is creating lingering uncertainty for the U.S. economy while scoffing at the notion that negative interest rates could help the world's largest economy regain its footing.
The major equity averages didn't do much of anything Tuesday even as several big names reported earnings before the opening bell. Fortunately, there was some decent commentary from those companies, albeit cautious, indicating that the U.S. economy could start rebounding in the second half of the year.
Merck (MRK) earnings for the pharmaceutical company's first quarter of 2020 have MRK stock falling Tuesday despite beating estimates.
Tuesday's big stock charts feature health-care-sector names that may offer value and leadership.
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.
Wednesday's big stock charts feature names that are preparing to meet with their significant support lines.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader